0001104659-24-071070.txt : 20240613 0001104659-24-071070.hdr.sgml : 20240613 20240613080525 ACCESSION NUMBER: 0001104659-24-071070 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240613 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 241040049 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 8-K 1 tm2417144d1_8k.htm FORM 8-K
false 0001267565 0001267565 2024-06-13 2024-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 13, 2024

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Virginia   001-37372   03-0416362
(State or Other Jurisdiction
of Incorporation or Organization)		   (Commission File Number)   (IRS Employer Identification
No.)

 

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 8.01  Other Information.

 

On June 13, 2024, Collegium Pharmaceutical, Inc. issued a press release announcing the U.S. Food and Drug Administration (“FDA”) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”), extending exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1 Press Release, dated June 13, 2024
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 13, 2024 Collegium Pharmaceutical, Inc.
     
  By: /s/ Colleen Tupper
    Name: Colleen Tupper
    Title: Executive Vice President and Chief Financial Officer

 

 

 

 EX-99.1 2 tm2417144d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

 

STOUGHTON, Mass., June 13, 2024 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27, 2025, to July 3, 2026. FDA’s grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER.

 

“We are pleased with FDA’s grant of pediatric exclusivity for the Nucynta Franchise,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve.”

 

Nucynta is currently approved in the U.S. for the management of acute pain severe enough to require an opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatments are inadequate in adults and pediatric patients aged six years and older with a body weight of at least 40 kg.

 

Nucynta ER is currently approved in the U.S. for the management of severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatment options are inadequate, and severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate.

 

Please see Important Safety Information that follows below and complete product information, including the Boxed Warning, available at www.NUCYNTA.com.

 

About Collegium Pharmaceutical, Inc.

 

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

 

NUCYNTA® (tapentadol) INDICATIONS AND USAGE

 

NUCYNTA® (tapentadol) tablets are:

 

·A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short term (acute) pain in adults and children 6 years of age and older who weigh at least 88 pounds (40 kg), when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.

 

 

 

 

 

 

·An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.

 

IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA TABLETS

 

 

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA TABLETS

 

Addiction, Abuse, and Misuse

Because the use of NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess regularly for the development of these behaviors and conditions.

 

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA tablets, especially during initiation of NUCYNTA tablets or following a dose increase. To reduce the risk of respiratory depression, proper dosing and titration of NUCYNTA tablets are essential.

 

Accidental Ingestion

Accidental ingestion of even one dose of NUCYNTA tablets, especially by children, can result in a fatal overdose of tapentadol.

 

Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of NUCYNTA tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

 

Neonatal Opioid Withdrawal Syndrome

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

 

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.

 

 

Important information about NUCYNTA tablets:

 

·Get emergency help or call 911 right away if you take too much NUCYNTA (overdose) tablets. When you first start taking NUCYNTA tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.

 

 

 

 

 

 

·Taking NUCYNTA tablets with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.

·Never give anyone else your NUCYNTA tablets. They could die from taking it. Selling or giving away NUCYNTA tablets is against the law.

·Store NUCYNTA tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.

 

Do not take NUCYNTA tablets if you have:

 

·severe asthma, trouble breathing, or other lung problems.

·a bowel blockage or have narrowing of the stomach or intestines.

 

Before taking NUCYNTA tablets, tell your healthcare provider if you have a history of:

 

·head injury, seizures

·problems urinating

·abuse of street or prescription drugs, alcohol addiction, opioid overdose or mental health problems

·liver, kidney, thyroid problems

·pancreas or gallbladder problems

 

Tell your healthcare provider if you:

 

·notice your pain getting worse. If your pain gets worse after you take NUCYNTA tablets, do not take more NUCYNTA tablets without first talking to your healthcare provider. Tell your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA tablets.

·are pregnant or planning to become pregnant. Use of NUCYNTA tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.

·are breastfeeding. NUCYNTA tablets pass into breast milk and may harm your baby.

·are living in a household where there are small children or someone who has abused street or prescription drugs.

·are taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA tablets with certain other medicines can cause serious side effects that could lead to death.

 

When taking NUCYNTA tablets:

 

·Do not change your dose. Take NUCYNTA tablets exactly as prescribed by your healthcare provider.

·Use the lowest dose possible for the shortest time needed.

·For acute (short-term) pain, you may only need to take NUCYNTA tablets for a few days. You may have some NUCYNTA tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused NUCYNTA tablets.

 

 

 

 

 

 

·Take your prescribed dose every 4-6 hours, at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.

·Call your healthcare provider if the dose you are taking does not control your pain.

·If you have been taking NUCYNTA tablets regularly, do not stop taking NUCYNTA tablets without talking to your healthcare provider.

·Dispose of expired, unwanted, or unused NUCYNTA Tablets by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

 

While taking NUCYNTA tablets, DO NOT:

 

·Drive or operate heavy machinery, until you know how NUCYNTA tablets affect you. NUCYNTA tablets can make you sleepy, dizzy, or lightheaded.

·Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with NUCYNTA tablets may cause you to overdose and die.

 

The possible side effects of NUCYNTA tablets:

 

·constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.

 

Get emergency medical help or call 911 right away if you have:

 

·trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.

 

These are not all of the possible side effects of NUCYNTA tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.

 

See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at Nucynta.com/IRpi. Speak to your healthcare provider if you have questions about Nucynta.

 

NUCYNTA® ER (tapentadol) INDICATIONS AND USAGE

 

NUCYNTA® ER (tapentadol) extended-release tablets are:

 

·A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage severe and persistent pain in adults that requires an extended treatment period with a daily opioid pain medicine, when other pain medicines do not treat your pain well enough or you cannot tolerate them.

·Also used in adults to manage severe and persistent pain from damaged nerves (neuropathic pain) that happens with diabetes, and that requires an extended treatment period with a daily opioid pain medicine, when other pain medicines do not treat your pain well enough or you cannot tolerate them.

 

 

 

 

 

 

·A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.

·Not to be taken on an “as needed” basis.

 

IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA ER

 

 

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA ER

 

Addiction, Abuse, and Misuse

Because the use of NUCYNTA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.

 

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA ER, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of NUCYNTA ER are essential. Instruct patients to swallow NUCYNTA ER tablets whole; crushing, chewing, or dissolving NUCYNTA ER tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol.

 

Accidental Ingestion

Accidental ingestion of even one dose of NUCYNTA ER, especially by children, can result in a fatal overdose of tapentadol. Interaction With Alcohol Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking NUCYNTA ER. The co-ingestion of alcohol with NUCYNTA ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol.

 

Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of NUCYNTA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

 

Neonatal Opioid Withdrawal Syndrome (NOWS)

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

 

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.

 

 

 

 

 

 

 

Important information about NUCYNTA ER:

 

·Get emergency help or call 911 right away if you take too much NUCYNTA ER (overdose). When you first start taking NUCYNTA ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.

·Taking NUCYNTA ER with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.

·Never give anyone else your NUCYNTA ER. They could die from taking it. Selling or giving away NUCYNTA ER is against the law.

·Store NUCYNTA ER securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.

 

Do not take NUCYNTA ER if you have:

 

·severe asthma, trouble breathing, or other lung problems.

·a bowel blockage or have narrowing of the stomach or intestines.

 

Before taking NUCYNTA ER, tell your healthcare provider if you have a history of:

 

·head injury, seizures

·problems urinating

·abuse of street or prescription drugs, alcohol addiction, opioid overdose or mental health problems

·liver, kidney, thyroid problems

·pancreas or gallbladder problems

 

Tell your healthcare provider if you:

 

·notice your pain getting worse. If your pain gets worse after you take NUCYNTA ER, do not take more of NUCYNTA ER without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA ER.

·are pregnant or planning to become pregnant. Use of NUCYNTA ER for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.

·are breastfeeding. Not recommended during treatment with NUCYNTA ER. It may harm your baby.

·are living in a household where there are small children or someone who has abused street or prescription drugs.

·are taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA ER with certain other medicines can cause serious side effects.

 

 

 

 

 

 

When taking NUCYNTA ER:

 

·Do not change your dose. Take NUCYNTA ER exactly as prescribed by your healthcare provider. Use the lowest effective dose for the shortest time needed.

·Take your prescribed dose every 12 hours, at the same time every day. Do not take more than your prescribed dose in 24 hours. If you miss a dose, take your next dose at your usual time.

·Swallow NUCYNTA ER whole. Do not cut, break, chew, crush, dissolve, snort, or inject NUCYNTA ER because this may cause you to overdose and die.

·Call your healthcare provider if the dose you are taking does not control your pain.

·Do not stop taking NUCYNTA ER without talking to your healthcare provider.

·Dispose of expired, unwanted, or unused NUCYNTA ER by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

 

While taking NUCYNTA ER, DO NOT:

 

·Drive or operate heavy machinery until you know how NUCYNTA ER affects you. NUCYNTA ER can make you sleepy, dizzy, or lightheaded.

·Drink alcohol or use prescription or over-the-counter medicines containing alcohol. Using products containing alcohol during treatment with NUCYNTA ER may cause you to overdose and die.

 

The possible side effects of NUCYNTA ER are:

 

·constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.

 

Get emergency medical help or call 911 right away if you have:

 

·trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.

·agitation, hallucinations, coma, feeling overheated, or heavy sweating.

 

These are not all the possible side effects of NUCYNTA ER. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.

 

See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, accompanying this piece or at Nucynta.com/ERpi. Speak to your healthcare provider if you have questions about Nucynta ER.

 

 

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

Investor Contact:

Christopher James, M.D.

Vice President, Investor Relations

ir@collegiumpharma.com

 

Media Contact:

Marissa Samuels

Vice President, Corporate Communications

communications@collegiumpharma.com

 

 

 

 EX-101.SCH 3 coll-20240613.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 coll-20240613_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 coll-20240613_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2417144d1_ex99-1img001.jpg GRAPHIC begin 644 tm2417144d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity File Number 001-37372
Entity Registrant Name COLLEGIUM PHARMACEUTICAL, INC.
Entity Central Index Key 0001267565
Entity Tax Identification Number 03-0416362
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 100 Technology Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Stoughton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02072
City Area Code 781
Local Phone Number 713-3699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol COLL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://collegiumpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports coll-20240613.xsd coll-20240613_lab.xml coll-20240613_pre.xml tm2417144d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2417144d1_8k.htm": { "nsprefix": "coll", "nsuri": "http://collegiumpharma.com/20240613", "dts": { "schema": { "local": [ "coll-20240613.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "coll-20240613_lab.xml" ] }, "presentationLink": { "local": [ "coll-20240613_pre.xml" ] }, "inline": { "local": [ "tm2417144d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://collegiumpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2417144d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2417144d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-071070-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-071070-xbrl.zip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end XML 18 tm2417144d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001267565 2024-06-13 2024-06-13 iso4217:USD shares iso4217:USD shares false 0001267565 8-K 2024-06-13 COLLEGIUM PHARMACEUTICAL, INC. VA 001-37372 03-0416362 100 Technology Center Drive Suite 300 Stoughton MA 02072 781 713-3699 Common stock, par value $0.001 per share COLL NASDAQ false false false false false